Coronavirus Update - 14th October 2020

Despite the recent rises in Covid-19 cases throughout the UK and Europe, Arcinova remains open for business at full capacity as we have done throughout this pandemic. As the situation continues to evolve, we will keep all our customers and stakeholders informed of our activities through this web-page which is updated on a regular basis.

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

Our work and case studies

Drug Product Case Study: Bringing the Manufacturing Process to Life Adapting from Terminal Sterilisation to Aseptic Manufacture

   

Drug Product Case Study: Accelerated Formulation

   

Drug Product Case Study: Intensive Manufacturing Programme

   

API Manufacture, Formulation Development, Capsule Product Manufacture Case Study

Challenge: Accelerate first-in-human and Phase II trials for an oral dosage form intended for treatment of CNS disorders. A fully integrated approach was required, to incl

Accelerated Development to Clinical Studies Rapid Manufacture - Precision Filling Case Study

Challenge: To rapidly manufacture a GMP-compliant API-in-capsule product for use in Phase I and Phase II clinical trials.  The product was being investigated for trea

Intravenous Formulation Phase 1 Study Challenge Case Study

Challenge: To develop stable sterile formulations of a drug substance for intravenous administration in phase I clinical trials.  The drug substance, intended for the

Chromatographic Development & Application Case Study

Challenge: Development of a modern, single, chromatographic procedure for a marketed tablet product that would allow the resolution and quantification of four active species and e

Biochemical Assay Case Study

Challenge: Build and validate an assay to measure non-haem iron in tissues thereby supporting one of the pivotal objectives for a regulatory non-clinical safety study.

Accelerated Manufacturing Case Study

Challenge: A strategy of rapid clinical progression – dose determination to manufacture and to patient administration within 4 days, necessitating a timeline of dose determinati